![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/time-runs-out-kronos-phase-3-aml-drug-biotech-blames-enrolment-struggles-ending-trial
https://www.prnewswire.com/news-releases/kronos-bio-and-invivoscribe-partner-on-companion-diagnostic-for-use-with-entospletinib-kronos-bios-investigational-compound-being-developed-for-patients-with-aml-301606955.html
https://www.globenewswire.com/news-release/2022/05/12/2442168/0/en/Kronos-Bio-s-Investigational-SYK-Inhibitors-Entospletinib-and-Lanraplenib-to-be-Featured-in-Four-Poster-Presentations-at-EHA2022-Congress.html